Design Therapeutics (DSGN) Q3 2026 earnings summary

Executive summary

• Clinical-stage pipeline spans Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type 1 (DM1) and Huntington’s disease (HD); no product revenue to date.

• Four-week RESTORE-FA data showed dose-dependent FXN biomarker increases and improvements across clinical measures; 12-week data are expected in Q1 2027.

Financial highlights

• Q3 2026 R&D expense was $16.9M versus $14.6M; G&A was $5.3M versus $4.7M; total operating expenses were $22.2M versus $19.3M.

• Q3 net loss was $20.3M versus $17.0M; interest income was $1.9M versus $2.3M.

• 9M 2026 R&D expense was $47.7M, G&A was $16.4M, total operating expenses were $64.1M versus $61.3M, and net loss was $58.1M versus $53.8M.

Outlook and guidance

• Cash, cash equivalents and investment securities of $208.6M are expected to fund planned expenses and capital requirements for more than 12 months after the report date; additional capital will be needed to advance candidates through approval.

• Expenses and operating losses are expected to rise as clinical programs advance, more candidates progress, and clinical, regulatory, quality and manufacturing capabilities expand.

• RESTORE-FA plans a 10-patient 12-week cohort at 1 mpk, a duration extension and exploration of a dose above 1 mpk; registrational-plan update expected Q4 2026 and 12-week data Q1 2027.

• DT-818 Phase 1 MAD data and DT-168 Phase 2 biomarker-trial data are expected in 2027.